👋 Hey, let’s get into it. Pfizer and Merck might want to reinforce the door, because Vaxcyte just delivered its “Here’s Johnny” moment in the pneumococcal vaccine market.

Its experimental vaccine, VAX-31, could challenge Pfizer and Merck’s established shots with broader coverage. It targets 31 types of pneumococcal bacteria, while Pfizer’s vaccine covers 20 and Merck’s covers 21.

Vaxcyte reported that it met the primary endpoints in a pivotal Phase 3 immune-response study, sending shares up around 27% by midday Monday. Its FDA filing is planned for the first half of 2028, giving Pfizer and Merck some time to upgrade the locks.

💰 Shionogi Agrees to Buy IntraBio for $2B
Shionogi agreed to acquire IntraBio for $2 billion upfront, adding Aqneursa and a rare-neurology business with a medicine already on the market. Aqneursa treats neurological manifestations of Niemann-Pick disease type C, an inherited disorder, and recently gained U.S. approval for ataxia, or coordination problems, associated with ataxia-telangiectasia in eligible patients. The acquisition gives Shionogi global rights to the drug alongside IntraBio’s development capabilities. Closing is expected in November or December, subject to conditions. Among this issue’s early-stage bets, Shionogi is buying a business that already has something to sell.

🤝 Sanofi Expands Regeneron Alliance in Deal Worth Up to $8B
Sanofi and Regeneron are renewing their relationship with four long-acting antibody programs and a $1 billion upfront payment. Another $7 billion depends on milestones, with development costs and future profits split equally. One antibody targeting the inflammatory signal IL-13 is in Phase 1; the other three are preclinical and expected to enter trials in 2027. The partners also settled their earlier collaboration litigation, while existing Dupixent economics stay intact. It’s an expensive relationship renewal, but the practical goal is clear: build the next immunology lineup with potentially less frequent dosing.

🧬 Novartis Signs Abogen mRNA Deal Worth Up to $7.8B
Novartis agreed to pay Abogen $575 million upfront for worldwide rights to ABO2203, an mRNA therapy already in clinical evaluation for autoimmune disease. Instead of supplying a finished therapeutic protein, it delivers instructions for the body to produce a T-cell engager that recruits T cells to remove B cells. The goal is a durable immune reset. Novartis also gets options on other RNA programs, with up to approximately $7.2 billion in milestones if all options are exercised and conditions met. The body gets the manufacturing instructions; researchers still have to establish the clinical payoff.

☢️ GE HealthCare’s $945M SOFIE Deal Tackles PET Delivery
GE HealthCare agreed to buy SOFIE Biosciences for $945 million in cash, bringing a network of 15 U.S. manufacturing sites for radioactive tracers used in PET scans. Those tracers lose activity over time, so producing them near imaging centers is critical. The deal also adds U.S. rights to FAPI-74, an investigational Phase 3 PET imaging agent with potential applications across cancers. Closing is expected in the first half of 2027. For GE, the acquisition connects its imaging business more closely to the medicines that make the scans possible…Be honest, did you read the title and think they were going to start delivering cats and dogs to your doorstep? No judgement here, just curious.

Stop hoping the algorithm finds your audience. They’re already here.

BioNucleus Briefing has 1,900+ subscriptions across its email and LinkedIn newsletters, including scientists, founders, investors, operators, and other biotech and pharma professionals.

We feature one exclusive sponsor per issue, giving relevant tools, software, services, events, and other life-science brands a direct way to reach our readers.

Think your company could be a fit? Reply to this email and let’s talk.

Alright, back to the newsletter.

🧠 Genentech Signs Parkinson’s Deal Worth Up to $1.27B
Genentech licensed Alector’s preclinical AL050 for $100 million upfront, aiming to deliver an engineered enzyme across the blood-brain barrier for Parkinson’s and other neurodegenerative diseases.

💸 Lilly Expands Gate Deal With Potential Value Above $870M
Lilly expanded its Gate Bioscience partnership for small molecules designed to eliminate disease-causing proteins by blocking their secretion, adding one target and an option for another.

🤝 CSL Signs Fibrosis Deal Worth Up to $1.6B
CSL committed $355 million upfront to partner on Alentis’ Phase 2 antibody lixudebart, funding further development for rare kidney and liver diseases.

⚠️ FDA Flags Serious Quality Failures at Fresenius Kabi
The FDA’s warning letter cited inadequate contamination investigations and sterile-manufacturing controls at Fresenius Kabi’s Illinois facility, including problems involving three recalled famotidine batches.

🤖 Xaira Shows Lab Results for AI-Designed Antibodies
Xaira reported lab-validated AI-designed antibody fragments that bind therapeutic targets, including six inhibitors of a difficult receptor target; the work remains preclinical.

🏭 Bayer Plans a $2.2B Ohio Manufacturing Site
Bayer plans a New Albany pharmaceutical campus with approximately 600 permanent jobs, targeting active-ingredient production in 2031 and finished medicines in 2034.

🎯 Genmab’s ADC Shows 45.9% Ovarian-Cancer Response Rate
Genmab’s investigational ADC, Rina-S, produced a 45.9% response rate in a single-arm Phase 2 platinum-resistant ovarian-cancer cohort, with median responses lasting 12.1 months.

💉 Lilly’s Amylin–GLP-1 Combo Delivers 23.3% Weight Loss
Phase 2b estimates showed 23.3% mean weight loss with eloralintide–tirzepatide versus 14.8% with tirzepatide in type 2 diabetes, but higher adverse-event discontinuations.

Your drug candidate can have cutting-edge biology and still spend months waiting for someone to finish a site agreement. The federal Advanced Research Projects Agency for Health, or ARPA-H, wants to tackle that mismatch. Its new SURPASS program aims to make clinical trials continuous and adaptive, with less repeated setup and earlier decisions as evidence accumulates. The ambition is faster trials. The starting point is the machinery that makes them run.

SURPASS combines predictive models for trial design, continuous statistical analysis, and software agents that automate operational work. A shared control group could serve as the comparison for multiple treatment arms, reducing duplication. Real-time analysis could help teams adjust studies sooner, while automation handles tasks such as onboarding new arms and cleaning data. Those changes require methods that keep conclusions reliable even when researchers examine results repeatedly. Checking the dashboard more often cannot become checking until the answer looks good.

The companion projects address problems an algorithm alone won’t solve. STACK aims to prepare more sites for research; COMMONS builds data infrastructure governed by patient and institutional permissions; CINCH helps patients contribute data and find suitable trials. UT Austin’s Dell Medical School will help test STACK and COMMONS, including reusable agreements and patient navigation. COMMONS validation will ask whether its data can reproduce established findings and reliably identify potentially eligible patients. That’s a useful test of whether better plumbing actually delivers better evidence.

This is a development agenda, with savings still to demonstrate. Predictive “digital twins” need validation, shared controls need appropriate comparisons, and patient protections still apply. For sponsors and sites, progress will mean less duplicated work and trustworthy results. The site-activation spreadsheet deserves retirement. It just needs a qualified replacement.

This is the approximate number of projects NIH funded in fiscal 2026, according to STAT, down from roughly 61,000 in 2025. The agency spent its full external-grants budget, but fewer projects and delayed decisions complicate research planning.

Here’s what biotech Redditors are talking about:

🏠 The Perfect Candidate Wants Three Work-From-Home Days
A hiring manager on Reddit thought they’d found their perfect candidate for an advertised on-site role. The candidate had agreed to that setup during interviews, then requested three work-from-home days during offer negotiations, along with a signing bonus to replace a missed year-end bonus. Most commenters saw the bonus as reasonable, but questioned changing the work arrangement so late. Apparently, the candidate thought “on-site” was just the opening offer.

🛫 Biotech Workers Discuss Their Exit Strategies
After three difficult biotech jobs in four years, a Redditor asked where people had landed after leaving the industry. Replies ranged from teaching and commercial roles to food manufacturing, logistics, and nursing. Others questioned whether switching industries would actually mean less stress or just different headaches. One process-development scientist floated becoming a Buddhist monk. You can picture the biotech-to-monk transition hitting a snag at salary negotiations. “Sir, there is no compensation package. That’s sort of the point.”

🐀 Plague Fears Follow Russian Lab Worker’s Death
An anti-plague institute worker’s death triggered hospital precautions and contact monitoring in Siberia. Reports raised fears of pneumonic plague, but the cause remains unconfirmed.

🏅 Nobel Prize in Medicine Honors Optogenetics Pioneers
Karl Deisseroth, Peter Hegemann, and Georg Nagel won for optogenetics, giving researchers a biological light switch to control genetically targeted cells.

🩸 Abbott Launches Blood Test for Colorectal Cancer
Abbott launched SimpleScreen for average-risk adults 45+ who decline preferred colorectal cancer screening methods. Positive results still require a follow-up colonoscopy.

🛰️ Varda Raises $251M for Drug Manufacturing in Space
Varda raised a $251 million Series D to scale pharmaceutical processing in orbit and deepen drug-development partnerships. The company uses microgravity to explore drug crystallization and formulation, then brings materials back to Earth in reentry capsules. It has completed six successful returns, with more than a dozen additional launches and reentries planned through 2028. The funding supports a more regular flight schedule as Varda works toward medicines made in space. Most manufacturing teams worry about shipping. This one also needs a heat shield.

🧠 October 6, 2014: The Brain’s GPS Wins a Nobel
On this day in 2014, John O’Keefe, May-Britt Moser, and Edvard Moser won the medicine Nobel for discoveries explaining the brain’s positioning system. O’Keefe identified hippocampal “place cells” in 1971, which activate in particular locations. In 2005, the Mosers identified “grid cells” in the entorhinal cortex, providing a repeating spatial coordinate system. Together, the discoveries helped explain how the brain represents location, linking navigation to memory. A Nobel-winning internal GPS, and yet I still lose my car after 30 minutes in the grocery store.

Thinking back to the work-from-home request in Community Vibes, imagine being the coworker who finds out the new hire gets three days at home while you’re still commuting five days a week.

Nothing stirs up the office like giving one person that flexibility while everyone in similar roles has to come in. There’s a non-zero chance someone stands on their desk and screams, “ANARCHY!”

That’s all for today. See you Thursday for the next issue. 👋

✍️ Today’s email was brought to you by Josh Martin. Connect with me on LinkedIn.

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead